Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... November 27, 2014 Calcivis, ... management of tooth decay, today announces that it ... Calcivis® Caries Activity Imaging System. The ... medical device and consumable combination designed to transform ... decay). It involves a unique, proprietary bioluminescence approach ...
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... and PHILADELPHIA , Nov. 26, 2014 ... and unforgiving environments. Human exploration of space requires astronauts ... ensure mission safety and success, and prevent potential errors ... mission success, little is known about how cognition is ... are primarily affected. Now, Penn Medicine researchers ...
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... and Yale universities have successfully transplanted most of the "nose" ... fruit flies and are employing these surrogates to combat the ... million people. The research is described in two complimentary ... of the Proceedings of the National Academy of Sciences ...
... ... World Europe conference in Brussels addresses the 4 key pillars of ... of the algae value chain. Panel of industry experts will also ... pharmaceuticals, nutraceuticals, cosmetics, aquaculture feed, bioplastics, coatings, etc. The program includes ...
... Feb. 12 CoAxia™, Inc. of Maple Grove, ... SENTIS randomized, controlled, pivotal trial of NeuroFlo™ Perfusion Augmentation Therapy ... plans to complete data collection and analysis of results in ... the US FDA. , Ischemic stroke is one of the ...
Cached Biology Technology:Scientists transplant nose of mosquito, advance fight against malaria 2Scientists transplant nose of mosquito, advance fight against malaria 32nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 22nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 3CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 2CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 3
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... King,s College London will today (Tuesday 6 December) announce ... (UKSCB) their first clinical grade human embryonic stem (hES) ... as ,xeno-free, stem cells. The cells, which have ... developing new stem cell-based therapies, will be the first ...
... Thanks to a new study of the retina, scientists ... how the nervous system becomes wired during early development. ... research at UCSB. The work is described in a recent ... research team examined the connectivity of nerve cells, called neurons, ...
... - Researchers have demonstrated a new imaging tool for ... the bloodstream, which could aid efforts to perfect their ... structures have potential applications in drug delivery to treat ... nanotubes are created in the manufacturing process, metallic and ...
Cached Biology News:Stem cell research in the UK reaches significant milestone 2Stem cell research in the UK reaches significant milestone 3Stem cell research in the UK reaches significant milestone 4UCSB scientists make advances in neuroscience and vision research 2UCSB scientists make advances in neuroscience and vision research 3'Label-free' imaging tool tracks nanotubes in cells, blood for biomedical research 2
... Kit, Protein, 1. Based on the ... the kit gives essentially colorless backgrounds ... Kit, Protein provides convenient, reproducible and ... gels in less than two hours.The ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
... • Guinea Pig serum is collected from ... N-02: Citrate N-04: Heparin ... Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA ...
Biology Products: